Prominently Increased of Mannose Binding Lectin (MBL) and Myeloperoxidase (MPO) Levels in Severe Valve Regurgitation and Heart Failure of Rheumatic Heart Disease

Authors

  • Rachmania Putri Department of Pediatrics, Saiful Anwar Hospital, Faculty of Medicine, Brawijaya University
  • Renny Suwarniaty Departments of Pediatrics, dr. Saiful Anwar General Hospital, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, Indonesia, 65111
  • Loeki Enggar Fitri Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, Indonesia, 65145
  • Susanto Nugroho Departments of Pediatrics, dr. Saiful Anwar General Hospital, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, Indonesia, 65111
  • Mohammad Saifur Rahman Departments of Cardiology and Vascular Medicine, dr. Saiful Anwar General Hospital, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia, 65111

DOI:

https://doi.org/10.11594/jtls.07.02.04

Keywords:

rheumatic heart disease, valvular regurgitation, heart failure, MBL, MPO

Abstract

Rheumatic heart disease (RHD) is mediated by an abnormal immunological response following a Streptococcus pyogenes infection that induces a disturbance of oxidants and antioxidants balances. Mannose-binding lectin (MBL) binds to N-acetylglucosamine, a molecule present on the Streptococcus cell wall and human heart valves. There is a disturbance of oxidant and antioxidant balance in rheumatic disease. Myeloperoxidase (MPO) is a marker of oxidative stress and inflammation. This study was aimed to determine the correlation of MBL and MPO levels and severity of valvular regurgitation and heart failure (HF) in RHD patients. A case-control study was conduct using human peripheral blood samples from 32 children aged 6 to 14 years old. The subjects were divided into two groups: 16 RHD patients included in the case group and 16 healthy children as a control group. The level of MBL and MPO was investigated using ELISA method. There were significant differences on MBL and MPO level between patient and control group. The level of MBL and MPO were significantly increased in RHD group, especially on severe valvular regurgitation. There was a strong correlation between MBL and MPO levels and the severity of valvular regurgitation (r = 0.94 and r = 0.88). The least significant diff-erence (LSD) analysis showed that significant difference occurs in the severe heart failure group. Our research revealed that the MBL and MPO levels in pediatric RHD patients were significantly higher than in healthy children. The MBL and MPO levels were significantly correlated with the severity of valvular regurgitation and heart failure.

References

Nayar S, Nayar PG, Cherian KM (2006) Heart valve structure: a predisposing factor for rheumatic heart disease. Heart 92 (8): 1151–1152.

Collard CD, Vakeva A, Morrissey MA et al. (2000) Complement activation after oxidative stress: role of the lectin complement pathway. The American Journal of Pathology 156 (5): 1549–1556. doi: 10.1016/S0002-9440(10)65026-2.

Schafranski M, Stier A, Reason IJ (2004) Signiï¬cantly increased levels of mannose-binding lectin (MBL) in rheumatic heart disease: a beneï¬cial role for MBL deï¬ciency. Clinical Experimental Immunology 138 (3): 521–525. doi: 10.1111/j.1365-2249.2004.02645.x.

Schafranski MD, Pereira Ferrari L, Scherner D et al. (2008) High-producing MBL2 genotypes increase the risk of acute and chronic carditis in patients with history of rheumatic fever. Molecular Immunology 45 (14): 3827–3831.

Karatas Z, Baysal T, Sap F et al. (2013) The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. The Anatolian Journal of Cardiology 13 (4): 350-356.

Uner A, Sal E, Dogan M et al. (2010) Investigation of oxidant and antioxidant pathway changes in acute rheumatic fever. Acta Cardiology 65 (1): 53-57.

Chen MC, Chang JP, Liu WH et al. (2009) Increased serum oxidative stress in patients with severe mitral regurgitation: a new finding and potential mechanism for atrial enlargement. Clinical Biochemistry 42 (10–11): 943–948.

Tang W, Brennan ML, Philip P et al. (2006) Plasma myeloperoxidase levels in patients with chronic heart failure. The American Journal of Cardiology 98 (6): 796 –799.

Morrow DA, Sabatine MS, Brennan ML et al. (2008) Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. European Heart Journal 29 (9): 1096–1102. doi: 10.1093/eurheartj/ehn071.

Heslop CL, Frohlich JJ, Hill JS (2010) Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. Journal of the American College of Cardiology 55 (11): 1102–1109. doi: 10.1016/j.jacc.2009.11.050.

Vita JA, Brennan ML, Gokce N et al. (2004) Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110 (9): 1134–1139.

Odobasic D, Yang Y, Muljadi RC et al. (2014) Endogenous myeloperoxidase is a mediator of joint inflammation and damage in experimental artritis. Artritis and Rheum, 66: 907-914.

WHO Technical Report Series (2004) Rheumatic fever and rheumatic heart disease. World Health Organization, Report No 923, Geneva,1–12.

Ross RD (2012) The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatric Cardiology 33 (8): 1295-1300. doi:10.1007/s00246-012-0306-8.

Madiyono B, Sukardi R, Kuswiyanto RB (2009) Demam reumatik dan penyakit jantung reumatik pada anak. In: Management of Pediatric Heart Diseases for Practitioners. From Early Detection to Intervention. Departemen Ilmu Kesehatan Anak FKUI-RSCM, 95-114.

Kironget AC (2014) Clinical profile of paediatric patients with rheumatic disease at Moi Teaching and Referral Hospital (MTRH) Kenya. Journal of Biology, Agriculture and Healthcare 2 (4): 2224-3208.

Beltrame MH, Catarino SJ, Goeldner I et al. (2015) The lectin pathway of complement and rheumatic heart disease. Frontiers in Pediatrics 2: 1–14. doi: 10.3389/fped.2014.00148.

Pradhan V, Surve P, Ghosh K (2010) Mannose binding lectin (MBL) in autoimmunity and its role in systemic lupus erythematosus (SLE). Journal of the Association of Physicians of India 58: 688-690.

Gombos T, Forhecz Z, Pozsonyi Z et al. (2012) Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure. Clinical Research in Cardiology 101 (8): 607–615. doi: 10.1007/s00392-012-0432-6.

Steyers CM, Miller FJ (2014) Endothelial dysfunction in chronic inflammatory diseases. International Journal of Molecular Sciences 15 (7): 11324-11349. doi: 10.3390/ijms150711324.

Stamp LK, Khalilova I, Tarr JM et al. (2012) Myeloperoxidase and oxidative stress in rheumatoid artritis. Rheumatology 193: 1-8.

Shanidze E, Zhvania M (2005) Activity of lipid peroxidation processes and the condition of antioxidative defense system in children with rheumatic fever. Georgian Med News 127: 38-40.

Chiu-Braga YY, Hayashi SY, Schafranski M, Messias-Reason IJ (2006) Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP). International Journal of Cardiology 109: 275-276.

Katz SD, Hryniewicz K, Hriljac I et al. (2005) Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111: 310-314.

Guilherme L, Cury P, Demarchi LM et al. (2004) Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. The American Journal of Pathology 165: 1583–1591.

Chen SJ, Yen CH, Huang YC et al. (2012) Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome. PLoS ONE 7 (9): e45693. doi:10.1371/journal.pone.0045693.

Grayburn PA (2008) How to measure severity of mitral regurgitation. Heart 94: 376-383.

Downloads

Published

2017-06-09

Issue

Section

Articles